Clinical Breast Cancer

Papers
(The H4-Index of Clinical Breast Cancer is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Editorial Board64
Can Women With HER2-Positive Metastatic Breast Cancer Be Cured?59
Editorial Board59
Comparison of the Pathological Complete Response Rate and Survival Between HER2-Low and HER2-Zero Breast Cancer in Neoadjuvant Chemotherapy Setting: A Systematic Review and Meta-Analysis51
Editorial Board49
Letter to the Editor regarding the article “Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World47
Corrigendum to “Prognostic and predictive impact of beta-2 adrenergic receptor expression in HER2-positive breast cancer” [Clin Breast Cancer 2020; 20:262–73.e7]40
Extended Clinical Experience With Nipple-Sparing Mastectomy and Prepectoral Polyurethane Implant Positioning (BRAND4P method)40
Intraoperative Touch Imprint Cytology in Breast Cancer Patients After Neoadjuvant Chemotherapy39
Circ_0108942 Regulates the Progression of Breast Cancer by Regulating the MiR-1178-3p/TMED3 Axis35
Table of Contents32
Genetic Ancestry of 1127 Brazilian Breast Cancer Patients and Its Correlation With Molecular Subtype and Geographic Region32
High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancer29
Comprehensive analysis of HER2 Low Breast Cancer Response to Neoadjuvant Chemotherapy, a Retrospective Cohort Study29
A Review of AI-Based Radiomics and Computational Pathology Approaches in Triple-Negative Breast Cancer: Current Applications and Perspectives29
The Impact of miRNAs on the Efficacy of Tamoxifen in Breast Cancer Treatment: A Systematic Review28
The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes28
Is Immediate Breast Reconstruction With a Latissimus Dorsi Myocutaneous Flap Safe for Starting Adjuvant Chemotherapy in Patients With Breast Cancer?28
Surgical-Site Infection is Associated With Increased Risk of Breast Cancer-Related Lymphedema: A Nationwide Cohort Study26
Shoulder function and health outcomes in newly diagnosed breast cancer patients receiving surgery: a prospective study26
Letter to the Editor of Clinical Breast Cancer, on “Time to Update Evidence-Based Guideline Recommendations About Concurrent Tamoxifen and Antidepressant Use? A Systematic Review,” Conducted by Michel23
The Ultrasonographic Characteristics of Focal Fibrocystic Change of the Breast and Analysis of Misdiagnosis23
Delayed Diagnosis and Prognostic Impact of Breast Cancer During the COVID-19 Pandemic22
Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors22
Tumour ki67 impact on survival in male breast cancer patients: a systematic review and meta-analysis22
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial22
Table of Contents22
A Dedicated Menopausal After Cancer Clinic May Improve Adherence to Endocrine Therapy For Breast Cancer: A Population Based Study22
0.31935906410217